聚乙二醇化重组人粒细胞集落刺激因子在预防宫颈癌同步放化疗后发生中性粒细胞减少症中的应用  

Application of pegylated recombinant human granulocyte-colony stimulating factor in the prevention of neutropenia after concurrent chemoradiotherapy for cervical cancer

作　　者：赵向荣 张振 高超 ZHAO Xiangrong;ZHANG Zhen;GAO Chao(Department of Radiotherapy,Liaocheng People’s Hospital,Liaocheng 252000,Shandong,China;Department of Radiotherapy,the Third Affiliated Hospital of Shandong First Medical University,Ji’nan 250000,Shandong,China)

机构地区：[1]聊城市人民医院放疗科,山东聊城252000 [2]山东第一医科大学第三附属医院放疗科,济南250000

出　　处：《癌症进展》2025年第6期676-679,共4页Oncology Progress

基　　金：山东省医学会临床科研资金-齐鲁专项(YXH2022ZX02214)。

摘　　要：目的探讨聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)在预防宫颈癌同步放化疗后发生中性粒细胞减少症中的应用效果。方法按照1∶1的比例随机将80例宫颈癌患者分为试验组(n=40)和对照组(n=40),同步放化疗期间,试验组患者使用PEG-rhG-CSF进行一级预防,对照组患者中性粒细胞计数绝对值(ANC)﹤1×10^(9)/L时使用重组人粒细胞集落刺激因子(rhG-CSF)。比较两组患者3~4级中性粒细胞减少症发生率和持续时间、4级中性粒细胞减少症发生率、中性粒细胞减少症伴发热(FN)发生率、放疗完成时间、化疗延迟率、化疗延迟时间及不良反应总发生率。结果试验组患者3~4级中性粒细胞减少症的发生率、4级中性粒细胞减少症的发生率、FN发生率、放疗完成时间、化疗延迟率、不良反应总发生率低于对照组,差异均有统计学意义(P﹤0.05)。两组患者3~4级中性粒细胞减少症持续时间、化疗延迟时间比较,差异均无统计学意义(P﹥0.05)。结论PEG-rhG-CS用于预防宫颈癌同步放化疗后发生中性粒细胞减少症的安全性高,不良反应总发生率低,可以有效降低3~4级中性粒细胞减少症、FN的发生率及化疗延迟率,缩短放疗时间。Objective To explore the application effect of pegylated recombinant human granulocyte-colony stimulating factor(PEG-rhG-CSF)in the prevention of neutropenia after concurrent chemoradiotherapy for cervical cancer.Method A total of 80 patients with cervical cancer were randomly divided into the experimental group(n=40)and the control group(n=40)at a ratio of 1:1.During concurrent chemoradiotherapy,patients in the experimental group received PEGrhG-CSF for primary prevention,while patients in the control group received recombinant human granulocyte-colonystimulating factor(rhG-CSF)when the absolute neutrophil count(ANC)was<1×10^(9)/L.The incidence and duration of grade 3-4 neutropenia,the incidence of grade 4 neutropenia,the incidence of febrile neutropenia(FN),the completion time of radiotherapy,the rate of chemotherapy delay,the duration of chemotherapy delay,and the total incidence of adverse reactions were compared between the two groups.Result The incidence of grade 3-4 neutropenia,the incidence of grade 4 neutropenia,the incidence of FN,the completion time of radiotherapy,the rate of chemotherapy delay,and the total incidence of adverse reactions in the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).There were no statistically significant differences in the duration of grade 3-4 neutropenia,and the duration of chemotherapy delay between the two groups(P>0.05).Conclusion PEG-rhG-CSF is safe and has a low total incidence of adverse reactions in the prevention of neutropenia after concurrent chemoradiotherapy for cervical cancer.It can effectively reduce the incidences of grade 3-4 neutropenia,FN and the rate of chemotherapy delay,and shorten the radiotherapy time.

关 键 词：宫颈癌 放化疗 中性粒细胞减少症 聚乙二醇化重组人粒细胞集落刺激因子 

分 类 号：R737.33[医药卫生—肿瘤]